Genmab A/S (OTCMKTS:GNMSF) Share Price Crosses Above 50-Day Moving Average - Here's Why

Key Points

• Genmab A/S's share price has crossed above its 50-day moving average of $222.02, reaching a high of $249.25 during trading.
• The company reported $5.42 earnings per share, exceeding expectations and contributing to a market capitalization of $16.47 billion.
• Genmab A/S specializes in developing antibody therapeutics for cancer treatment, with notable products including DARZALEX for multiple myeloma.

Genmab A/S (OTCMKTS:GNMSF - Get Free Report)'s share price crossed above its 50-day moving average during trading on Tuesday . The stock has a 50-day moving average of $222.02 and traded as high as $249.25. Genmab A/S shares last traded at $249.25, with a volume of 131 shares traded.

Genmab A/S Stock Performance

The company has a market cap of $16.47 billion, a PE ratio of 12.51 and a beta of 0.90. The stock's 50-day simple moving average is $222.02 and its 200 day simple moving average is $211.38.

Genmab A/S (OTCMKTS:GNMSF - Get Free Report) last issued its earnings results on Thursday, August 7th. The company reported $5.42 earnings per share for the quarter, beating the consensus estimate of $3.99 by $1.43. The business had revenue of $925.00 million for the quarter, compared to the consensus estimate of $949.06 million. Genmab A/S had a net margin of 37.53% and a return on equity of 21.03%.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.